- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03489759
The Effect of Vitamin E-coated Polysulfone Membrane on Oxidative Stress, Inflammation and Monocytes in Critically Ill Patients in CRRT (Vitabrane E)
The Effect of Vitamin E-coated Polysulfone Membrane on Oxidative Stress, Inflammation and Monocytes in Critically Ill Patients in CRRT: a Pilot, Randomized, Double-blinded, No-profit, Clinical Study
The study evaluate the effect of a membrane in polysulfone covered with vitamin E (ViE15-A, ASAHI Kasey, Tokyo, Japan) versus non-vitamin E polysulfone membrane (REXEED-15A, ASAHI Kasey, Tokyo, Japan) in critically ill patients admitted to intensive care undergoing continuous extracorporeal dialysis (CRRT).
The current randomized study is designed to assess the effect on the levels of oxidative stress, pro and anti-inflammatory cytokines and the mode and amount of death of monocytic cell lines using ViE 15-A in comparison withe REXEED-15A.
The investigators hypothezise that the ViE15-A versus REXEED-15A will have different effect on the levels of oxidative stress, pro and anti-inflammatory cytokines and the mode and amount of death of monocytic cell lines.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study evaluate the effect of a membrane in polysulfone covered with vitamin E (ViE15-A, ASAHI Kasey, Tokyo, Japan) on the levels of oxidative stress, pro and anti-inflammatory cytokines and the mode and amount of death of monocytic cell lines in critically ill patients admitted to intensive care undergoing continuous extracorporeal dialysis (CRRT).
This membrane will be compared with a non-vitamin E polysulfone membrane (REXEED-15A, ASAHI Kasey, Tokyo, Japan) and already intended for use in continuous renal support therapy.
The current randomized study is designed to assess the effect on the levels of oxidative stress, pro and anti-inflammatory cytokines and the mode and amount of death of monocytic cell lines using ViE 15-A in comparison withe REXEED-15A.
Precisely, will be evaluated
- the effect of the filter on the reduction of the plasma levels of two pro-inflammatory cytokines (IL-1β and IL-6) and of two anti-inflammatory cytokines (IL-10, IL-8);
- the analysis of the life modality of the monocytic cells: the patient's plasma will be used, incubated for 24 hours with U937 cells (monocyte precursor cells), necrosis cells and the percentage of apoptotic cells. The apoptotic cells will also evaluate the apoptotic pathway (evaluation of activated caspases) that led to cell death. The differences that are highlighted in the two different sampling moments become expressed Δ% with respect to the initial value Secondary outcomes will be to evaluate the clinical outcomes (haemodynamic and hematochemical parameters) in the short and long term deriving from the application of a membrane with vitamin E; for this reason, for the whole duration of the extracorporeal dialysis therapy, the same filter assigned to the patient at the time of enrollment will be used.
All the other parameters of the extracorporeal treatment that can influence the results will be standardized; in particular, the flows will be fixed according to the dialysis dose criteria and re-infusion methods according to the table in the paragraph "treatment characteristics".
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Vicenza, Italy, 36100
- Recruiting
- San Bortolo Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age > 18 years
- Acute Kidney Injury
- ICU patients with clinical indication for Continuous Renal Replacement Therapy
- Clinical decision to begin CVVH for at least 24 hours with high flux filter (defined as membranes with an ultrafiltration coefficient KUF > 25ml/Kg/h)
- Obtain the informed consent
Exclusion Criteria:
- Hemodialysis patients, peritoneal dialysis patients and transplant recipient;
- Hypothermia (T < 36°C)
- Regional Anticoagulation with Citrate
- Septic Shock;
- Neoplasm in Chemotherapy
- Extra-Corporeal Membrane Oxygenation
- Cardio Circulatory Arrest
- Autoimmune disease or immunosuppressed patients;
- Life expectancy < 24 hr
- Pregnancy;
- Informed Consent refused by the patient or surrogate decision-maker
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ViE15-A
The patients were randomly allocated to two groups by using computer-generated numbers.
The renal replacement therapy will be started using ViE15-A hemofilter
|
The type of dialytic treatment that will be used during the study will be continuous venous hemofiltration (CVVH-Continuous veno-venous hemofiltration).
The filter will be ViE15-A.
|
Active Comparator: REXEED-15A
TThe patients were randomly allocated to two groups by using computer-generated numbers.
The renal replacement therapy will be started using REXEED-15A
|
The type of dialytic treatment that will be used during the study will be continuous venous hemofiltration (CVVH-Continuous veno-venous hemofiltration).
The filter will be REXEED-15A.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Copper/Zinc
Time Frame: change from 24 to 72 hours
|
In vivo comparison of ROS concentrations in two groups
|
change from 24 to 72 hours
|
Superoxide Dismutas
Time Frame: change from 24 to 72 hours
|
In vivo comparison of ROS concentrations in two groups
|
change from 24 to 72 hours
|
Endogenous peroxidase activity
Time Frame: change from 24 to 72 hours
|
In vivo comparison of ROS concentrations in two groups
|
change from 24 to 72 hours
|
Nitric Oxide
Time Frame: change from 24 to 72 hours
|
In vivo comparison of ROS concentrations in two groups
|
change from 24 to 72 hours
|
Viability
Time Frame: change from 24 to 72 hours
|
Ex vivo comparison of relative decrease of monocytes cell line incubated in plasma
|
change from 24 to 72 hours
|
Apoptosis
Time Frame: change from 24 to 72 hours
|
Ex vivo comparison of relative decrease of monocytes cell line incubated in plasma
|
change from 24 to 72 hours
|
Necrosis
Time Frame: change from 24 to 72 hours
|
Ex vivo comparison of relative decrease of monocytes cell line incubated in plasma
|
change from 24 to 72 hours
|
Interleukine-6
Time Frame: change from 24 to 72 hours
|
In vivo comparison of relative reductions of inflammatory cytokines concentrations in two groups
|
change from 24 to 72 hours
|
Interleukine -10
Time Frame: change from 24 to 72 hours
|
In vivo comparison of relative reductions of inflammatory cytokines concentrations in two groups
|
change from 24 to 72 hours
|
Interleukine-18
Time Frame: change from 24 to 72 hours
|
In vivo comparison of relative reductions of inflammatory cytokines concentrations in two groups
|
change from 24 to 72 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of CRRT-free days from enrollment to ICU discharge in two groups
Time Frame: 7 days
|
The assessment of the effect of both hemofilters on short term clinical renal outcomes
|
7 days
|
Comparison of mechanical Ventilation-free days from enrollment to ICU discharge in two groups
Time Frame: 7 days
|
The assessment of the effect of both hemofilters on short term clinical renal outcomes
|
7 days
|
Comparison of vasopressor drugs-free days in two groups
Time Frame: 7 days
|
The assessment of the effect of both hemofilters on short term clinical renal outcomes
|
7 days
|
Comparison of ICU length of stay in two groups
Time Frame: 7 days
|
The assessment of the effect of both hemofilters on short term clinical renal outcomes
|
7 days
|
Comparison of renal recovery in two groups
Time Frame: 7 days
|
The assessment of the effect of both hemofilters on short term clinical renal outcomes
|
7 days
|
Comparison of CRRT-free days from enrollment to hospital discharge in two groups
Time Frame: 90 days
|
The assessment of the effect of both hemofiltes on long term clinical renal outcomes
|
90 days
|
Comparison of need of (Intermittent Hemodialysis) IHD at hospital discarge in patients treated with vitamine E-coated membrane and non-vitamin E-coated membrane
Time Frame: 90 days
|
The assessment of the effect of both hemofiltes on long term clinical renal outcomes
|
90 days
|
Comparison of renal recovery at hospital discharge in two groups
Time Frame: 90 days
|
The assessment of the effect of both hemofiltes on long term clinical renal outcomes
|
90 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Claudio Ronco, MD, Department of Nephrology, Dialysis and Transplantation
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 79/16A
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Failure
-
University of Sao Paulo General HospitalUnknownRenal Transplant Rejection | Graft Failure | Transplant; Failure, Kidney | Chronic Renal Failure (CRF)Brazil
-
Angiodynamics, Inc.TerminatedChronic Kidney Disease | Acute Kidney Injury | Acute Renal Failure | Renal Failure Chronic Contrast InducedUnited States
-
Rockwell Medical Technologies, Inc.CompletedRenal Failure Chronic Requiring HemodialysisUnited States, Puerto Rico
-
Rockwell Medical Technologies, Inc.CompletedRenal Failure Chronic Requiring HemodialysisUnited States, Canada
-
Washington University School of MedicineCompletedAcute Renal Failure | Chronic Renal FailureUnited States
-
University Hospital, Clermont-FerrandRecruitingAcute Kidney Injury | Transient Acute Renal Failure | Persistent Acute Renal FailureFrance
-
University Hospital, GhentCompletedAcute Renal Failure | Chronic Renal FailureBelgium
-
The University of Hong KongHospital Authority, Hong KongCompletedEnd-stage Renal Failure (ESRF)Hong Kong
-
The Hong Kong Polytechnic UniversityHospital Authority, Hong KongCompletedPalliative Care | Renal Failure, End-stageHong Kong
-
PfizerCompletedChronic Renal Failure Requiring HemodialysisUnited States, Puerto Rico
Clinical Trials on ViE15-A
-
Johnson & Johnson Vision Care, Inc.Completed
-
Johnson & Johnson Vision Care, Inc.CompletedCorneal Infiltrative Events | Corneal InflammationUnited States
-
Johnson & Johnson Vision Care, Inc.Completed
-
Coopervision, Inc.Completed
-
Bausch & Lomb IncorporatedCompleted
-
Johnson & Johnson Vision Care, Inc.Completed
-
Johnson & Johnson Vision Care, Inc.CompletedVisual AcuityUnited States
-
Johnson & Johnson Vision Care, Inc.University of ManchesterCompleted
-
University of OttawaCompletedBorderline Personality Disorder | Deliberate Self Harm